Inhibition of Growth Factor Activity by Suramin and Related Compounds
Author Information
Author(s): P.S. Braddock, D.-E. Hu, T.-P.D. Fan, I.J. Stratford, A.L. Harris, R. Bicknell
Primary Institution: Imperial Cancer Research Fund, University of Oxford
Hypothesis
Can structurally related polyanions to suramin effectively inhibit the growth factor and angiogenic activity of basic fibroblast growth factor (bFGF)?
Conclusion
Certain polyanions related to suramin can inhibit bFGF-stimulated growth and angiogenesis while being less toxic.
Supporting Evidence
- Polyanions with extended ring structures were more effective in blocking bFGF activity.
- Some polyanions were found to be 5- to 10-fold less toxic than suramin.
- CPD14 showed equivalent antiangiogenic activity to suramin in vivo.
Takeaway
Some new medicines can stop bad cells from growing without making you sick, like how some toys can be fun without being dangerous.
Methodology
The study involved testing various polyanions for their ability to inhibit bFGF-stimulated cell growth and angiogenesis in vitro and in vivo using a rat sponge model.
Potential Biases
Potential bias in the selection of compounds and the interpretation of results based on the structural similarities to suramin.
Limitations
The study primarily focused on a limited number of polyanions and their effects in specific models, which may not fully represent clinical scenarios.
Participant Demographics
The study used bovine and human endothelial cells, as well as mice for in vivo experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website